Advertisement

Immunologic Research

, Volume 46, Issue 1–3, pp 216–226 | Cite as

Enhancement of anti-tumor immunity by photodynamic therapy

  • Sandra O. Gollnick
  • Craig M. Brackett
Article

Abstract

Photodynamic therapy (PDT) is an FDA-approved modality that rapidly eliminates local tumors, resulting in cure of early disease and palliation of advanced disease. PDT was originally considered to be a local treatment; however, both pre-clinical and clinical studies have shown that local PDT treatment of tumors can enhance systemic anti-tumor immunity. The current state of investigations into the ability of PDT to enhance anti-tumor immunity, the mechanisms behind this enhancement and the future of PDT as an immunotherapy are addressed in this review.

Keywords

PDT Neutrophil Vaccine T cell 

Notes

Acknowledgments

This work was supported by NIH Grants CA55791 and CA98156 and in part by the Roswell Park Cancer Center Support Grant CA16056.

References

  1. 1.
    Brown SB, Brown EA, Walker I. The present and future role of photodynamic therapy in cancer treatment. Lancet Oncol. 2004;5:497–508.CrossRefPubMedGoogle Scholar
  2. 2.
    Dougherty TJ. An update on photodynamic therapy applications. J Clin Laser Med Surg. 2002;20:3–7.CrossRefPubMedGoogle Scholar
  3. 3.
    MacDonald IJ, Dougherty TJ. Basic principles of photodynamic therapy. J Porphy Phthalocyan. 2001;5:105–29.CrossRefGoogle Scholar
  4. 4.
    McBride G. Studies expand potential uses of photodynamic therapy. J Natl Cancer Inst (Bethesda). 2002;94:1740–2.Google Scholar
  5. 5.
    Patrice T, Olivier D, Bourre L. PDT in clinics: indications, results, and markets. J Environ Pathol Toxicol Oncol. 2006;25:467–85.PubMedGoogle Scholar
  6. 6.
    Henderson BW, Gollnick SO. Mechanistic principles of photodynamic therapy. In: Vo-Dinh T, editor. Biomedical photonics handbook. Boca Raton: CRC Press; 2003.Google Scholar
  7. 7.
    Evans S, Matthews W, Perry R, Fraker D, Norton J, Pass HI. Effect of photodynamic therapy on tumor necrosis factor production by murine macrophages. J Natl Cancer Inst. 1990;82:34–9.CrossRefPubMedGoogle Scholar
  8. 8.
    Kick G, Messer G, Goetz A, Plewig G, Kind P. Photodynamic therapy induces expression of interleukin 6 by activation of AP-1 but not NF-kB DNA binding. Cancer Res. 1995;55:2373–9.PubMedGoogle Scholar
  9. 9.
    Gollnick SO, Evans SE, Baumann H, et al. Role of cytokines in photodynamic therapy-induced local and systemic inflammation. Br J Cancer. 2003;88:1772–9.CrossRefPubMedGoogle Scholar
  10. 10.
    Gollnick SO, Liu X, Owczarczak B, Musser DA, Henderson BW. Altered expression of interleukin 6 and interleukin 10 as a result of photodynamic therapy in vivo. Cancer Res. 1997;57:3904–9.PubMedGoogle Scholar
  11. 11.
    Korbelik M, Krosl G, Krosl J, Dougherty GJ. The role of host lymphoid populations in the response of mouse EMT6 tumor to photodynamic therapy. Cancer Res. 1996;56:5647–52.PubMedGoogle Scholar
  12. 12.
    Korbelik M. Induction of tumor immunity by photodynamic therapy. J Clin Laser Med & Surg. 1996;14:329–34.Google Scholar
  13. 13.
    Korbelik M, Dougherty GJ. Photodynamic therapy-mediated immune response against subcutaneous mouse tumors. Cancer Res. 1999;59:1941–6.PubMedGoogle Scholar
  14. 14.
    Henderson BW, Gollnick SO, Snyder JW, et al. Choice of oxygen-conserving treatment regimen determines the inflammatory response and outcome of photodynamic therapy of tumors. Cancer Res. 2004;64:2120–6.CrossRefPubMedGoogle Scholar
  15. 15.
    de Vree WJ, Essers MC, De Bruijn HS, Star WM, Koster JF, Sluiter W. Evidence for an important role of neutrophils in the efficacy of photodynamic therapy in vivo. Cancer Res. 1996;56:2908–11.PubMedGoogle Scholar
  16. 16.
    Korbelik M, Cecic I. Contribution of myeloid and lymphoid host cells to the curative outcome of mouse sarcoma treatment by photodynamic therapy. Cancer Lett. 1999;137:91–8.CrossRefPubMedGoogle Scholar
  17. 17.
    Fleming TJ, Fleming ML, Malek TR. Selective expression of Ly-6G on myeloid lineage cells in mouse bone marrow. RB6–8C5 mAb to granulocyte-differentiation antigen (Gr-1) detects members of the Ly-6 family. J Immunol. 1993;151:2399–408.PubMedGoogle Scholar
  18. 18.
    Nakano H, Yanagita M, Gunn MD. CD11c(+)B220(+)Gr-1(+) cells in mouse lymph nodes and spleen display characteristics of plasmacytoid dendritic cells. J Exp Med. 2001;194:1171–8.CrossRefPubMedGoogle Scholar
  19. 19.
    Nakano H, Lin KL, Yanagita M, et al. Blood-derived inflammatory dendritic cells in lymph nodes stimulate acute T helper type 1 immune responses. Nat Immunol. 2009;10:394–402.CrossRefPubMedGoogle Scholar
  20. 20.
    Cecic I, Parkins CS, Korbelik M. Induction of systemic neutrophil response in mice by photodynamic therapy of solid tumors. Photochem Photobiol. 2001;74:712–20.CrossRefPubMedGoogle Scholar
  21. 21.
    Cecic I, Stott B, Korbelik M. Acute phase response-associated systemic neutrophil mobilization in mice bearing tumors treated by photodynamic therapy. Int Immunopharmacol. 2006;6:1259–66.CrossRefPubMedGoogle Scholar
  22. 22.
    Cecic I, Korbelik M. Mediators of peripheral blood neutrophilia induced by photodynamic therapy of solid tumors. Cancer Lett. 2002;183:43–51.CrossRefPubMedGoogle Scholar
  23. 23.
    de Vree WJ, Essers MC, Koster JF, Sluiter W. Role of interleukin 1 and granulocyte colony-stimulating factor in photofrin-based photodynamic therapy of rat rhabdomyosarcoma tumors. Cancer Res. 1997;57:2555–8.PubMedGoogle Scholar
  24. 24.
    Ziolkowski P, Symonowicz K, Milach J, Szkudlarek T. In vivo tumor necrosis factor-alpha induction following chlorin e6-photodynamic therapy in Buffalo rats. Neoplasma. 1996;44:192–6.Google Scholar
  25. 25.
    Nseyo UO, Whalen RK, Duncan MR, Berman B, Lundahl SL. Urinary cytokines following photodynamic therapy for bladder cancer. Urology. 1990;36:167–71.CrossRefPubMedGoogle Scholar
  26. 26.
    Yom SS, Busch TM, Friedberg JS, et al. Elevated serum cytokine levels in mesothelioma patients who have undergone pleurectomy or extrapleural pneumonectomy and adjuvant intraoperative photodynamic therapy. Photochem Photobiol. 2003;78:75–81.CrossRefPubMedGoogle Scholar
  27. 27.
    Canti G, De Simone A, Korbelik M. Photodynamic therapy and the immune system in experimental oncology. Photochem Photobiol Sci. 2002;1:79–80.CrossRefPubMedGoogle Scholar
  28. 28.
    Castano AP, Mroz P, Hamblin MR. Photodynamic therapy and anti-tumour immunity. Nat Rev Cancer. 2006;6:535–45.CrossRefPubMedGoogle Scholar
  29. 29.
    Canti G, Lattuada D, Nicolin A, Taroni P, Valentini G, Cubeddu R. Immunopharmacology studies on photosensitizers used in photodynamic therapy (PDT). Proc SPIE Photodyn Ther Cancer. 1994;2078:268–75.Google Scholar
  30. 30.
    Schreiber S, Gross S, Brandis A, et al. Local photodynamic therapy (PDT) of rat C6 glioma xenografts with Pd-bacteriopheophorbide leads to decreased metastases and increase of animal cure compared with surgery. Int J Cancer. 2002;99:279–85.CrossRefPubMedGoogle Scholar
  31. 31.
    van Duijnhoven FH, Aalbers RI, Rovers JP, Terpstra OT, Kuppen PJ. Immunological aspects of photodynamic therapy of liver tumors in a rat model for colorectal cancer. Photochem Photobiol. 2003;78:235–40.CrossRefPubMedGoogle Scholar
  32. 32.
    Momma T, Hamblin MR, Wu HC, Hasan T. Photodynamic therapy of orthotopic prostate cancer with benzoporphyrin derivative: local control and distant metastasis. Cancer Res. 1998;58:5425–31.PubMedGoogle Scholar
  33. 33.
    Gomer CJ, Ferrairo A, Murphree AL. The effect of localized porphyrin photodynamic therapy on the induction of tumour metastasis. Br J Cancer. 1987;56:27–32.PubMedGoogle Scholar
  34. 34.
    Blank M, Lavie G, Mandel M, Keisari Y. Effects of photodynamic therapy with hypericin in mice bearing highly invasive solid tumors. Oncol Res. 2001;12:409–18.Google Scholar
  35. 35.
    Castano AP, Gad R, Zahra T, Hamblin MR. Specific anti-tumor immune response with photodynamic therapy mediated by benzoporphyrin derivative and chlorin(e6). In: Jacques SL, Duncan DD, Kirkpatrick SJ, Kriete A, editors. 4961 ed. The International Society for Optical Engineering. Proceedings of SPIE; 2003.Google Scholar
  36. 36.
    Kabingu E, Vaughan L, Owczarczak B, Ramsey KD, Gollnick SO. CD8+ T cell-mediated control of distant tumours following local photodynamic therapy is independent of CD4+ T cells and dependent on natural killer cells. Br J Cancer. 2007;96:1839–48.CrossRefPubMedGoogle Scholar
  37. 37.
    Castellino F, Germain RN. Cooperation between CD4+ and CD8+ T cells: when, where, and how. Annu Rev Immunol. 2006;24:519–40.CrossRefPubMedGoogle Scholar
  38. 38.
    Marzo AL, Vezys V, Klonowski KD, et al. Fully functional memory CD8 T cells in the absence of CD4 T cells. J Immunol. 2004;173:969–75.PubMedGoogle Scholar
  39. 39.
    Wang J, Santosuosso M, Ngai P, Zganiacz A, Xing Z. Activation of CD8 T cells by mycobacterial vaccination protects against pulmonary tuberculosis in the absence of CD4 T cells. J Immunol. 2004;173:4590–7.PubMedGoogle Scholar
  40. 40.
    Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol. 1994;12:991–1045.PubMedGoogle Scholar
  41. 41.
    Kaisho T, Akira S. Regulation of dendritic cell function through Toll-like receptors. Curr Mol Med. 2003;3:373–85.CrossRefPubMedGoogle Scholar
  42. 42.
    Bullock TN, Yagita H. Induction of CD70 on dendritic cells through CD40 or TLR stimulation contributes to the development of CD8+ T cell responses in the absence of CD4+ T cells. J Immunol. 2005;174:710–7.PubMedGoogle Scholar
  43. 43.
    Ridge JP, DiRosa F, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature. 1998;393:474–8.CrossRefPubMedGoogle Scholar
  44. 44.
    van Mierlo GJ, Boonman ZF, Dumortier HM, et al. Activation of dendritic cells that cross-present tumor-derived antigen licenses CD8+ CTL to cause tumor eradication. J Immunol. 2004;173:6753–9.PubMedGoogle Scholar
  45. 45.
    Gollnick SO, Owczarczak B, Maier P. Photodynamic therapy and anti-tumor immunity. Lasers Surg Med. 2006;38:509–15.CrossRefPubMedGoogle Scholar
  46. 46.
    Lee HK, Iwasaki A. Innate control of adaptive immunity: dendritic cells and beyond. Semin Immunol. 2007;19:48–55.CrossRefPubMedGoogle Scholar
  47. 47.
    Cavallo F, Giovarelli M, Gulino A, et al. Role of neutrophils and CD4+ T lymphocytes in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene. J Immunol. 1992;149:3627–35.PubMedGoogle Scholar
  48. 48.
    Graf MR, Prins RM, Merchant RE. IL-6 secretion by a rat T9 glioma clone induces a neutrophil-dependent antitumor response with resultant cellular, antiglioma immunity. J Immunol. 2001;166:121–9.PubMedGoogle Scholar
  49. 49.
    Stoppacciaro A, Melani C, Parenza M, et al. Regression of an established tumor genetically modified to release granulocyte colony-stimulating factor requires granulocyte-T cell cooperation and T cell-produced interferon gamma. J Exp Med. 1993;178:151–61.CrossRefPubMedGoogle Scholar
  50. 50.
    Kousis PC, Henderson BW, Maier PG, Gollnick SO. Photodynamic therapy (PDT) enhancement of anti-tumor immunity is regulated by neutrophils. Cancer Res. 2007;67:10501–10.CrossRefPubMedGoogle Scholar
  51. 51.
    Nathan C. Neutrophils and immunity: challenges and opportunities. Nat Rev Immunol. 2006;6:173–82.CrossRefPubMedGoogle Scholar
  52. 52.
    van Gisbergen KP, Geijtenbeek TB, van Kooyk Y. Close encounters of neutrophils and DCs. Trends Immunol. 2005;26:626–31.CrossRefPubMedGoogle Scholar
  53. 53.
    Bennouna S, Denkers EY. Microbial antigen triggers rapid mobilization of TNF-alpha to the surface of mouse neutrophils transforming them into inducers of high-level dendritic cell TNF-alpha production. J Immunol. 2005;174:4845–51.PubMedGoogle Scholar
  54. 54.
    Ethuin F, Gerard B, Benna JE, et al. Human neutrophils produce interferon gamma upon stimulation by interleukin-12. Lab Invest. 2004;84:1363–71.CrossRefPubMedGoogle Scholar
  55. 55.
    Gollnick SO, Vaughan LA, Henderson BW. Generation of effective anti-tumor vaccines using photodynamic therapy. Cancer Res. 2002;62:1604–8.PubMedGoogle Scholar
  56. 56.
    Zhang H, Ma W, Li Y. Generation of effective vaccines against liver cancer by using photodynamic therapy. Lasers Med Sci. 2009;24:549–52.CrossRefPubMedGoogle Scholar
  57. 57.
    Korbelik M, Cecic I. Mechanism of tumor destruction by photodynamic therapy. In: Nalwa HS, editor. Handbook of photochemistry and photobiology. Stevenson Ranch: American Scientific Publishers; 2003.Google Scholar
  58. 58.
    Korbelik M, Sun J. Photodynamic therapy-generated vaccine for cancer therapy. Cancer Immunol Immunother. 2006;55:900–9.CrossRefPubMedGoogle Scholar
  59. 59.
    Jalili A, Makowski M, Switaj T, et al. Effective photoimmunotherapy of murine colon carcinoma induced by the combination of photodynamic therapy and dendritic cells. Clin Cancer Res. 2004;10:4498–508.CrossRefPubMedGoogle Scholar
  60. 60.
    Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245–52.CrossRefPubMedGoogle Scholar
  61. 61.
    Lanzavecchia A, Sallusto F. Regulation of T cell immunity by dendritic cells. Cell. 2001;106:263–6.CrossRefPubMedGoogle Scholar
  62. 62.
    Mellman I, Steinman RM. Dendritic cells: specialized and regulated antigen processing machines. Cell. 2001;106:255–8.CrossRefPubMedGoogle Scholar
  63. 63.
    Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol. 2001;2:675–80.CrossRefPubMedGoogle Scholar
  64. 64.
    Schnare M, Barton GM, Holt AC, Takeda K, Akira S, Medzhitov R. Toll-like receptors control activation of adaptive immune responses. Nat Immunol. 2001;2:947–50.CrossRefPubMedGoogle Scholar
  65. 65.
    Martinon F, Tschopp J. NLRs join TLRs as innate sensors of pathogens. Trends Immunol. 2005;26:447–54.CrossRefPubMedGoogle Scholar
  66. 66.
    Fritz JH, Ferrero RL, Philpott DJ, Girardin SE. Nod-like proteins in immunity, inflammation and disease. Nat Immunol. 2006;7:1250–7.CrossRefPubMedGoogle Scholar
  67. 67.
    Meylan E, Tschopp J, Karin M. Intracellular pattern recognition receptors in the host response. Nature. 2006;442:39–44.CrossRefPubMedGoogle Scholar
  68. 68.
    Janeway CA. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol. 1989;54:1–13.PubMedGoogle Scholar
  69. 69.
    Fuchs EJ, Matzinger P. Is cancer dangerous to the immune system? Semin Immunol. 1996;8:271–80.CrossRefPubMedGoogle Scholar
  70. 70.
    Matzinger P. The danger model: a renewed sense of self. Science. 2002;296:301–5.CrossRefPubMedGoogle Scholar
  71. 71.
    Bowie A, O’Neill LA. The interleukin-1 receptor/Toll-like receptor superfamily: signal generators for pro-inflammatory interleukins and microbial products. J Leukoc Biol. 2000;67:508–14.PubMedGoogle Scholar
  72. 72.
    Mariathasan S, Monack DM. Inflammasome adaptors and sensors: intracellular regulators of infection and inflammation. Nat Rev Immunol. 2007;7:31–40.CrossRefPubMedGoogle Scholar
  73. 73.
    Karin M, Lawrence T, Nizet V. Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell. 2006;124:823–35.CrossRefPubMedGoogle Scholar
  74. 74.
    Dougherty TJ, Gomer CJ, Henderson BW, et al. Photodynamic therapy. J Natl Cancer Inst. 1998;90:889–905.CrossRefPubMedGoogle Scholar
  75. 75.
    Oleinick NL, Evans HH. The photobiology of photodynamic therapy: cellular targets and mechanisms. Radiat Res. 1998;150(5 Suppl):S146–56.CrossRefPubMedGoogle Scholar
  76. 76.
    Korbelik M, Sun J, Cecic I. Photodynamic therapy-induced cell surface expression and release of heat shock proteins: relevance for tumor response. Cancer Res. 2005;65:1018–26.PubMedGoogle Scholar
  77. 77.
    Thong PS, Ong KW, Goh NS, et al. Photodynamic-therapy-activated immune response against distant untreated tumours in recurrent angiosarcoma. Lancet Oncol. 2007;8:950–2.CrossRefPubMedGoogle Scholar
  78. 78.
    Vabulas RM, Wagner H, Schild H. Heat shock proteins as ligands of toll-like receptors. Curr Top Microbiol Immunol. 2002;270:169–84.PubMedGoogle Scholar
  79. 79.
    Gomer CJ, Ryter SW, Ferrairo A, Ryffel N, Woodard A, Fisher AMR. Photodynamic therapy-mediated oxidative stress can induce expression of heat shock proteins. Cancer Res. 1996;56:2355–60.PubMedGoogle Scholar
  80. 80.
    Gollnick SO, Kabingu E, Kousis PC, Henderson BW. Stimulation of the host immune response by photodynamic therapy (PDT). In: Jacques SL, Duncan DD, Kirkpatrick SJ, Kriete A, editors. 5315 ed. The International Society for Optical Engineering. Proceedings of SPIE; 2004.Google Scholar
  81. 81.
    Stott B, Korbelik M. Activation of complement C3, C5, and C9 genes in tumors treated by photodynamic therapy. Cancer Immunol Immunother. 2006;56:649–58.CrossRefPubMedGoogle Scholar
  82. 82.
    Savill J, Dransfield I, Gregory C, Haslett C. A blast from the past: clearance of apoptotic cells regulates immune responses. Nat Rev Immunol. 2002;2:965–75.CrossRefPubMedGoogle Scholar
  83. 83.
    Abdel-Hady ES, Martin-Hirsch P, Duggan-Keen M, et al. Immunological and viral factors associated with the response of vulval intraepithelial neoplasia to photodynamic therapy. Cancer Res. 2001;61:192–6.PubMedGoogle Scholar
  84. 84.
    Dragieva G, Hafner J, Dummer R, et al. Topical photodynamic therapy in the treatment of actinic keratoses and Bowen’s disease in transplant recipients. Transplantation. 2004;77:115–21.CrossRefPubMedGoogle Scholar
  85. 85.
    Chuang P–T, McMahon AP. Vertebrate hedgehog signalling modulated by induction of a hedgehog-binding protein. Nature. 1999;397:617–21.CrossRefPubMedGoogle Scholar
  86. 86.
    Ingham PW. The patched gene in development and cancer. Curr Opin Genet Dev. 1998;8:88–94.CrossRefPubMedGoogle Scholar
  87. 87.
    Wicking C, Smyth I, Bale A. The hedgehog signalling pathway in tumorigenesis and development. Oncogene. 1999;18:7844–51.CrossRefPubMedGoogle Scholar
  88. 88.
    Bonifas JM, Pennypacker S, Chuang P–T, et al. Activation of expression of hedgehog target genes in basal cell carcinomas. J Invest Dermatol. 2001;116:739–42.CrossRefPubMedGoogle Scholar
  89. 89.
    Tojo M, Kiyosawa H, Iwatsuki K, Kaneko F. Expression of a sonic hedgehog signal transducer, hedgehog-interacting protein, by human basal cell carcinoma. Br J Derm. 2002;146:69–73.CrossRefGoogle Scholar
  90. 90.
    Vogt A, Chuang PT, Hebert J, et al. Immunoprevention of basal cell carcinomas with recombinant hedgehog-interacting protein. J Exp Med. 2004;199:753–61.CrossRefPubMedGoogle Scholar
  91. 91.
    Kabingu E, Oseroff AR, Wilding GE, Gollnick SO. Enhanced systemic immune reactivity to a basal cell carcinoma associated antigen following photodynamic therapy. Clin Cancer Res. 2009;15:4460–6.CrossRefPubMedGoogle Scholar
  92. 92.
    Thong PS, Olivo M, Kho KW, et al. Immune response against angiosarcoma following lower fluence rate clinical photodynamic therapy. J Environ Pathol Toxicol Oncol. 2008;27:35–42.PubMedGoogle Scholar
  93. 93.
    Granville DJ, Levy JG, Hunt DWC. Photodynamic treatment with benzoporphyrin derivative monoacid ring A produces protein tyrosine phosphorylation events and DNA fragmentation in murine P815 cells. Photochem Photobiol. 1998;67:358–62.CrossRefPubMedGoogle Scholar
  94. 94.
    Hunt DW, Levy JG. Immunomodulatory aspects of photodynamic therapy. Expert Opin Investig Drugs. 1998;7:57–64.CrossRefPubMedGoogle Scholar
  95. 95.
    Friedberg JS, Mick R, Stevenson JP, et al. Phase II trial of pleural photodynamic therapy and surgery for patients with non-small-cell lung cancer with pleural spread. J Clin Oncol. 2004;22:2192–201.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.Department of ImmunologyRoswell Park Cancer InstituteBuffaloUSA
  2. 2.Department of Cell Stress BiologyRoswell Park Cancer InstituteBuffaloUSA

Personalised recommendations